Moderna, Inc. — Director's Dealing 2020

May 20, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-05-19

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-19	Common Stock	M	12563	$12.21	Acquired	12563	Direct
2020-05-19	Common Stock	M	112481	$12.21	Acquired	125044	Direct
2020-05-19	Common Stock	S	125044	$78.16	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-05-19	Stock Option (Right to Buy)	$12.21	M	12563	Disposed	2027-02-23	Common Stock (12563)	Direct
2020-05-19	Stock Option (Right to Buy)	$12.21	M	112481	Disposed	2027-10-03	Common Stock (112481)	Direct

Footnotes

F1: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F2: 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

F3: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).